Lunai Bioworks Inc. (NASDAQ:LNAI) — Market Cap & Net Worth
Market Cap & Net Worth: Lunai Bioworks Inc. (LNAI)
Lunai Bioworks Inc. (NASDAQ:LNAI) has a market capitalization of $11.97 Million ($11.97 Million) as of July 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26535 globally and #5458 in its home market, demonstrating a -22.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lunai Bioworks Inc.'s stock price $2.02 by its total outstanding shares 36271119 (36.27 Million). Review LNAI current and long-term liabilities to assess the company's total debt and financial obligations.
Lunai Bioworks Inc. Market Cap History: 2025 to 2026
Lunai Bioworks Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $31.98 Million to $73.27 Million (0.00% CAGR).
Lunai Bioworks Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lunai Bioworks Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LNAI by Market Capitalization
Companies near Lunai Bioworks Inc. in the global market cap rankings as of July 31, 2026.
Key companies related to Lunai Bioworks Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #537 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #556 globally with a market cap of $47.90 Billion USD ( ₩70.69 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $481.70 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $738.34 |
| #537 | Argen-X | BR:ARGX | $49.55 Billion | €746.60 |
| #556 | Samsung Biologics Co Ltd | KO:207940 | $47.90 Billion | ₩1527000.00 |
Lunai Bioworks Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Lunai Bioworks Inc.'s market cap moved from $31.98 Million to $ 73.27 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $73.27 Million | +129.10% |
| 2025 | $31.98 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 31st, 2026 the market cap of Lunai Bioworks Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.97 Million USD |
| MoneyControl | $11.97 Million USD |
| MarketWatch | $11.97 Million USD |
| marketcap.company | $11.97 Million USD |
| Reuters | $11.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; a… Read more